Invivyd (NASDAQ:IVVD – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.
Institutional & Insider Ownership
70.4% of Invivyd shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 12.2% of Invivyd shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Invivyd and Neuphoria Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Invivyd | $53.43 million | 3.17 | -$52.49 million | ($0.33) | -1.74 |
| Neuphoria Therapeutics | $1.17 million | 12.91 | -$13.45 million | ($6.22) | -0.45 |
Neuphoria Therapeutics has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Invivyd has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Invivyd and Neuphoria Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Invivyd | 1 | 2 | 3 | 0 | 2.33 |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Invivyd presently has a consensus target price of $10.00, suggesting a potential upside of 1,639.13%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 150.81%. Given Invivyd’s stronger consensus rating and higher possible upside, equities analysts plainly believe Invivyd is more favorable than Neuphoria Therapeutics.
Profitability
This table compares Invivyd and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Invivyd | -183.90% | -59.73% | -48.97% |
| Neuphoria Therapeutics | N/A | -38.31% | -28.92% |
Summary
Invivyd beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
